Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Control BionicsASX:CBL +7.81% EV-to-EBIT is -4.36 as of Jul. 25, 2026. The stock has 4 warning signs investors should review. Among 465 Medical Devices & Instruments companies, Control Bionics ranks worse than 215053.55% on this metric.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Control Bionics's Enterprise Value for the quarter that ended in Dec. 2025 was A$22.31 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Control Bionics's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was A$-6.40 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Control Bionics EV-to-EBIT Related Terms
Control Bionics EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Control Bionics's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Control Bionics's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Control Bionics EV-to-EBIT vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Control Bionics's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Control Bionics's EV-to-EBIT falls into.
Control Bionics's current Enterprise Value is A$27.91 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Control Bionics's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was A$-6.40 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Control Bionics (ASX:CBL) has a EV-to-EBIT of -4.36 as of Jul. 25, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Control Bionics and its competitors. According to the industry distribution chart, Control Bionics ranks #999999 out of 465 companies in the Medical Devices & Instruments industry.
Is Control Bionics' EV-to-EBIT too high?
Control Bionics' current EV-to-EBIT is -4.36. Based on the distribution chart, Control Bionics ranks #999999 out of 465 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers.
How does Control Bionics' EV-to-EBIT compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Control Bionics ranks #999999 out of 465 companies for EV-to-EBIT. This places Control Bionics in the lower half of its industry. The industry median EV-to-EBIT is 18.19. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Medical Devices & Instruments company?
The median EV-to-EBIT among Medical Devices & Instruments companies is 18.19, based on 465 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Control Bionics and its competitors. For the Medical Devices & Instruments industry, the median EV-to-EBIT is 18.19 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Control Bionics's current EV-to-EBIT is -4.36. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Control Bionics stock overvalued right now?
Based on GuruFocus' analysis, Control Bionics (ASX:CBL) is currently considered Significantly Overvalued. The stock's GF Value™ is A$0.03, compared to a current price of A$0.07 — trading 130% above its estimated fair value. The current EV-to-EBIT is -4.36. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Control Bionics (ASX:CBL), the current EV-to-EBIT is -4.36 as of Jul. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Control Bionics Ltd is engaged in the healthcare device business. It is involved in developing, commercializing, and selling assistive communications technology systems within the disability sector. Its core systems include NeuroNode Trilogy and NeuroNode3. These systems allow people with speech and movement difficulties to control a computer for speech generation, electronic communications, entertainment, and external control of other devices. Geographically, it derives a majority of revenue from North America and has its presence in Australia as well.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:CBL has been successfully added to your 
